The Journal of Experimental Medicine· 2013Q1

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

Rikke Holmgaard, Dmitriy Zamarin, David H. Munn, Jedd D. Wolchok et al.

637citations
Q1SCImago
2013year

Short summary

Blocking indoleamine 2,3-dioxygenase (IDO) synergizes with CTLA-4 blockade to reject tumors, even those not expressing IDO, by increasing effector T cells and reducing regulatory T cells.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Biological Psychiatry

Biological PsychiatryNeuroscience